checkAd
    Startseite > Aktien > BiomX > Nachrichten
    BiomX Aktie
    0,3456
     
    USD
    -0,12 %
    -0,0004 USD
    Letzter Kurs 19:22:17 NYSE Arca
    0,3456
     
    USD
    200 STK
    Geldkurs 20:14:01
    0,3839
     
    USD
    100 STK
    Briefkurs 20:14:01
    ISIN: US09090D1037 · WKN: A2P9A0 · SYM: PHGE · USA

    Neueste Nachrichten

    BiomX to Host First Quarter 2024 Financial Results Conference Call and Webcast on May 21, 2024
    13:00 Uhr · globenewswire · BiomX
    BiomX to Present Data from Phase 1b/2a Study of BX004 for the Treatment of Cystic Fibrosis Patients with Chronic Pulmonary Infections at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2024)
    23.04.24 · globenewswire · BiomX
    BiomX Announces the Appointment of Susan Blum to its Board of Directors
    18.04.24 · globenewswire · BiomX
    BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure
    04.04.24 · globenewswire · BiomX
    BiomX Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
    03.04.24 · globenewswire · BiomX
    BiomX to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on April 3rd, 2024
    27.03.24 · globenewswire · BiomX
    BiomX Announces Closing of the Acquisition of Adaptive Phage Therapeutics and Concurrent $50 Million Financing
    18.03.24 · globenewswire · BiomX
    BiomX Announces Entry into Merger Agreement with Adaptive Phage Therapeutics and Concurrent $50 Million Financing
    06.03.24 · globenewswire · BiomX
    BiomX Receives Orphan Drug Designation from the U.S. Food and Drug Administration for BX004 for the Treatment of Chronic Pulmonary Infection Caused by Pseudomonas aeruginosa in Patients with Cystic Fibrosis
    04.01.24 · globenewswire · BiomX
    BiomX Announces Positive Topline Results from Part 2 of the Phase 1b/2a Trial Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis
    29.11.23 · globenewswire · BiomX
    BiomX Reports Third Quarter 2023 Financial Results and Provides Business Update
    14.11.23 · globenewswire · BiomX
    BiomX to Present Data from Ongoing Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis at the 37th Annual North American Cystic Fibrosis Conference
    27.10.23 · globenewswire · BiomX